Plasma p-Tau217 Testing
A blood-based biomarker of Alzheimer-type tau pathology. Plasma phosphorylated tau 217 (p-tau217) reflects early Alzheimer disease brain pathology in people who are still cognitively unimpaired, and as of 2026 can be translated into time-specific absolute risk estimates for progression to cognitive impairment.
Evidence Summary
UPDATE (October 13, 2026): The clinical case for plasma p-tau217 has been reinforced by regulatory and head-to-head evidence. In May 2025 the US FDA cleared the first blood test to aid Alzheimer diagnosis - the Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio (Fujirebio Diagnostics), indicated for adults aged 55 and older who already show signs and symptoms of cognitive impairment. A 2025 Nature Medicine study (Palmqvist et al.) validated a fully automated plasma p-tau217 assay across five primary- and secondary-care cohorts against CSF/PET reference standards: using a two-cutoff strategy, diagnostic accuracy reached 92% in primary care and 92-94% in secondary care, with only 12-17% of results falling in an intermediate zone. This builds on the landmark 2024 JAMA primary- and secondary-care study (Palmqvist et al., >1,200 patients), in which a p-tau217-based score was about 90% accurate versus about 73% for dementia specialists and about 61% for primary-care physicians using standard clinical assessment. Importantly, the FDA clearance is for symptomatic adults; using p-tau217 for risk stratification in cognitively unimpaired people remains off-label and belongs within careful counselling. Verified sources: FDA news release, May 16, 2025 (https://www.fda.gov/news-events/press-announcements/fda-clears-first-blood-test-used-diagnosing-alzheimers-disease); Palmqvist et al., Nature Medicine 2025;31:2036-2043 (https://doi.org/10.1038/s41591-025-03622-w); Palmqvist et al., JAMA 2024, Blood Biomarkers to Detect Alzheimer Disease in Primary Care and Secondary Care (https://jamanetwork.com/journals/jama/fullarticle/2821669). Peer-reviewed human evidence for prognosis is now substantial. A JAMA 2026 pooled analysis (Buckley et al.) harmonized six longitudinal cohorts across North America, Japan and Australia (n=2,684 cognitively unimpaired adults, median follow-up 5.4 years, maximum 13.5 years, 478 progression events). Each 1-SD increase in baseline plasma p-tau217 carried a hazard ratio of 1.38 (95% CI 1.30-1.46) for progression to cognitive impairment, and 1.32 (1.24-1.41) after adjustment including amyloid-PET Centiloids. Critically, the study reports ABSOLUTE rather than relative risk: 24% (95% CI 20-28%) five-year risk at high p-tau217 (1.1-2.4 SD) and 38% (95% CI 33-43%) at very high (>2.5 SD). Elevated p-tau217 also predicted faster cognitive decline, independently of and synergistically with amyloid-PET burden. The important caveat is that these were selected research and clinical-trial cohorts; absolute risk figures will differ in unselected primary-care populations, and the authors call for validation there before individual prognostic use. Nature Aging 2026 (Bellomo, Vermunt, del Campo et al.) reports a large multicentre plasma proteomics study identifying blood biomarkers that discriminate Alzheimer's disease, dementia with Lewy bodies and frontotemporal dementia, and that support molecular staging within disease. This matters for how p-tau217 is positioned: most blood-based neurodegeneration work to date, including p-tau217, addresses the AD-versus-not question, whereas differential diagnosis across syndromes is the harder and more clinically consequential problem - and it is where a single-analyte AD-specific marker is least informative. Assay standardisation across platforms and prospective validation in unselected memory-clinic populations remain outstanding, and cohort-based discrimination performance typically overstates real-world performance. This is not yet a deployable panel and does not displace p-tau217.
Evidence Scale
Mechanism of Action
Tau becomes pathological when hyperphosphorylated at specific residues. Phosphorylation at threonine 217 is closely coupled to early amyloid-driven tau pathology, and the resulting p-tau217 fragment is detectable in plasma. Circulating levels rise years before clinical symptoms, tracking the underlying neurodegenerative process rather than downstream cognitive decline.
Who Is This For?
Consider in adults with a family history of Alzheimer disease, subjective cognitive complaints, APOE4 carriage, or those seeking to quantify neurodegenerative risk as part of a comprehensive longevity assessment. Requires that the patient genuinely wants the information and has been counselled beforehand.
Protocol & Dosing
Dose
Not a dosed intervention. Assay platforms differ in cut-points; results should be interpreted against the specific laboratory's reference distribution, ideally expressed in standard deviations rather than raw concentration.
Frequency
Single test; repeat interval not established by evidence
Duration
N/A
Protocol Summary
Single venous blood draw, processed on a validated immunoassay platform. Best interpreted alongside clinical assessment, cognitive testing and, where indicated, amyloid imaging or CSF studies. Repeat testing intervals are not established.
Latest Evidence
2025: the first FDA-cleared Alzheimer's blood test - and 92% real-world accuracy
In May 2025 the US FDA cleared the first blood test to aid Alzheimer diagnosis - the Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio (Fujirebio Diagnostics) - for adults aged 55 and older who already show signs and symptoms of cognitive impairment. A 2025 Nature Medicine study (Palmqvist et al.) then validated a fully automated plasma p-tau217 assay across five real-world primary- and secondary-care cohorts: with a two-cutoff strategy, diagnostic accuracy reached 92% in primary care and 92-94% in specialist care against CSF/PET reference standards, leaving only 12-17% of results in an intermediate zone.
This builds on the landmark 2024 JAMA study of more than 1,200 patients, in which a p-tau217-based score was about 90% accurate versus about 73% for dementia specialists and about 61% for primary-care physicians using standard assessment (charted below). For prognosis in people who are still cognitively unimpaired, a 2026 pooled analysis translated p-tau217 into absolute five-year risk of progression - roughly 24% at high levels and 38% at very high levels - though those figures come from selected research cohorts, not everyday practice.
Plasma p-tau217 is an aid to diagnosis and risk assessment, not a stand-alone diagnosis, and no treatment follows automatically from a result. The FDA clearance is for symptomatic adults 55+; use in asymptomatic longevity screening is off-label and should be counselled beforehand. Results must be interpreted by a qualified clinician alongside the full clinical picture. Educational information, not medical advice.
Prospective study · diagnostic accuracy vs clinical assessment · >1,200 patients
A p-tau217 blood score outperformed clinicians' standard Alzheimer's diagnosis
Bars show diagnostic accuracy against a CSF/PET reference standard in a 2024 study of more than 1,200 patients (515 in primary care, 698 in secondary/specialist care). A p-tau217-based score (APS2) was about 90% accurate, compared with about 73% for dementia specialists and about 61% for primary-care physicians using their standard clinical workup. A blood test is an aid to diagnosis, not a diagnosis on its own, and results must be interpreted by a clinician alongside the full clinical picture. Source: Palmqvist et al., Blood Biomarkers to Detect Alzheimer Disease in Primary Care and Secondary Care, JAMA (2024). Educational information, not medical advice.
Related on Peak Human
Diagnostic & Biomarker Testing
Physician-ordered blood and biomarker testing with interpretation.
p-Tau 181/217 Biomarker
What phosphorylated-tau markers measure and how to read them.
APOE Genotype
Genetic risk that helps decide who benefits most from testing.
Comprehensive Blood Panel
Where neurodegeneration markers fit a full longevity panel.
Genetic Testing
Risk-stratify who should consider p-tau217 testing.
Plasmalogens for Brain Health
Related reading on nutrients studied for brain aging.
p-Tau217 Absolute Risk (JAMA 2026)
The pooled analysis behind the five-year risk figures.
Brain Fog
How cognitive concerns are worked up at Peak Human.
Cognitive-Support Supplements
Curated supplements studied for brain and cognitive health.
Key references: FDA clears first blood test to aid Alzheimer diagnosis - Lumipulse G pTau217 (2025) · Palmqvist et al. - Fully automated plasma p-tau217 in primary and secondary care, Nature Medicine (2025) · Palmqvist et al. - Blood biomarkers to detect Alzheimer disease in primary and secondary care, JAMA (2024)
Interactions & Precautions
Contraindications
- Patient unwilling or unprepared to receive a probabilistic risk result
- Absence of pre- and post-test counselling
- Use as a standalone diagnostic in symptomatic patients without full clinical workup
Potential Risks
- •No proven disease-modifying action follows automatically from a high result
- •Absolute risk estimates derive from selected cohorts and may not transfer to general practice
- •Assay standardization across platforms remains incomplete
Potential Side Effects
Practitioner Notes
Clinical annotations from Dr. Goel
Counsel before ordering, not after. The value of this test is that it converts a diffuse worry into a number - but that number is probabilistic, and a 38% five-year risk means a 62% chance of no progression. Frame the result as a prompt for aggressive modifiable-risk management (blood pressure, glycemic control, sleep apnea, hearing loss, physical activity, alcohol, cardiovascular risk) rather than as a diagnosis. Note that the JAMA 2026 absolute-risk figures come from selected research cohorts, so quote them as orientation rather than as this patient's number. Do not present anti-amyloid therapy eligibility as an automatic consequence of an elevated result. Updated August 16, 2026: When a patient with cognitive symptoms has a normal or equivocal p-tau217, resist treating that as reassurance about neurodegeneration generally - it is an AD-weighted marker, and DLB and FTD are precisely the syndromes it will not flag. The Nature Aging 2026 multicentre proteomics work points toward panels that discriminate between dementias rather than screening for one, but it is not clinically available and has not been validated prospectively in unselected memory-clinic populations. For now the practical implication is a communication one: state explicitly what a p-tau217 result does and does not rule out, and keep clinical phenotyping and specialist referral primary. Updated October 13, 2026: Note that the FDA clearance (May 2025, Lumipulse G pTau217/β-Amyloid 1-42) is for adults 55+ who already have cognitive signs and symptoms - using p-tau217 as a screening or risk-stratification tool in asymptomatic longevity patients is off-label, and should be framed and consented as such.
Dr. Sanjeev Goel
Chief Medical Officer, Peak Human
Cost & Access
Cost Range
$200-$500 CAD depending on platform and laboratory
Accessibility
Availability varies by location
Sample member
Longevity Operator
One number for your longevity journey.
FICO for credit. PHS for longevity. Eight biological domains collapsed into one provable score — intuitive at a glance, rigorous underneath.
- Metabolic
- Hormonal
- Cardiovascular
- Brain / Cognitive
- Sleep
- Musculoskeletal
- Gut
- Immunity / Inflammation
